Morepen Labs Shares Surge Over 10% Today: Here's What's Driving the Rally

Spread love

By S. JHA

Morepen Labs shares gained over 10% today. Here’s a look at the stock’s recent trend, key technical levels, and latest financial performance.

Mumbai, June 30, 2026 — Shares of Morepen Laboratories Ltd jumped more than 10% in trade today, extending a volatile run for the pharmaceutical company over the past few weeks. The stock has been among the more actively discussed names in the BSE Healthcare basket, with the exchange itself recently flagging unusual volume activity in the counter.

Morepen Labs has had a sharp swing in recent sessions. The stock’s 52-week range stretches from a low of around ₹33 to a high of roughly ₹70.50, meaning today’s move places it well off its bottom but still short of its yearly peak.

Earlier this month, the BSE sought a clarification from the company after a sudden spike in trading volumes; Morepen responded that there were no pending price-sensitive disclosures and that the activity appeared to be market-driven.

The counter has also seen news flow around a large CDMO (contract development and manufacturing) mandate from a global pharma major, reported to be worth roughly ₹825 crore over multiple years, as well as the launch of Empamore, positioned by the company as a new treatment option for Type 2 diabetes. Moves of this kind, a large new order win paired with a fresh product launch, are typically the sort of news that can reignite investor interest in a small-cap pharma name.

Technical Snapshot

With today’s gain, Morepen Labs is trading well above recent support built around the ₹33-44 zone seen earlier this year. A double-digit single-day move of this scale generally signals a breakout attempt, and traders will likely watch whether the stock can hold above its short-term moving averages on a closing basis or whether the move fades into profit-booking, a common pattern after sharp one-day rallies in mid- and small-cap stocks.

The next meaningful technical hurdle sits in the vicinity of the stock’s 52-week high near ₹70-71; a sustained move past that zone would mark a fresh yearly high, while failure to hold today’s gains could see the stock retest levels closer to ₹45-50.

Financial Performance

Morepen Labs’ recent quarterly numbers have been mixed depending on the reporting period and consolidation basis. For the March 2026 quarter, the company’s standalone net profit was reported to have declined year-on-year to around ₹15.7 crore, with EBITDA margins compressing to roughly 5%.

On a consolidated basis for FY26, however, the company reported gross revenue growth of about 22% to roughly ₹472 crore for the year, with net profit rising sharply. The company’s board also recommended a final dividend for the year and approved a second addendum to its Business Transfer Agreement with subsidiary Morepen Medipath, revising the appointed date to April 1, 2026.

On valuation, the stock has traded at a price-to-earnings ratio in the mid-20s in recent sessions, with a price-to-book ratio above 2, levels that suggest the market has already been pricing in some growth expectations even before today’s rally.

Separately, the company’s Masulakhanna manufacturing facility recently completed a USFDA inspection with zero observations, marking its fourth consecutive clean inspection in eight years, a regulatory clean chit that can support sentiment for a pharma exporter reliant on US market access.

What to Watch Next

Investors will likely track whether trading volumes stay elevated in the coming sessions, any further disclosures from the company following the exchange’s clarification request, and progress on the newly announced CDMO mandate, which management has flagged as a move into the higher-growth contract manufacturing segment. Quarterly results and commentary on the Empamore launch’s commercial traction will also be key data points for the stock going forward.

(This article is for informational purposes only and does not constitute investment advice. Readers should consult a registered financial advisor before making any investment decisions.)

Zydus Wellness Jumps Over 9% as Massive Volume Confirms Breakout

FAQs:

Why did Morepen Labs shares rise today?

The stock extended a recent rally amid elevated trading volumes, with newsflow around a large CDMO order win and the launch of a new diabetes treatment, Empamore, supporting sentiment.

What is Morepen Labs’ 52-week high and low?

The stock’s 52-week range has been roughly ₹33 on the low end to around ₹70.50 on the high end.

Has Morepen Labs declared a dividend recently?

Yes, the board recommended a final dividend for FY26 alongside its annual results.

What does Morepen Labs manufacture?

The company makes active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products including diagnostic devices under the Dr. Morepen brand.

Follow The Raisina Hills on WhatsApp, Instagram, YouTube, Facebook, and LinkedIn